Immunomodulators as objects of the pharmaceutical market. Message III. The product conjuncture of immunosuppressants and their place in the state guarantees program of medical care of the population

Abstract

Immunosuppressants (ІS) are used to prevent a number of autoimmune diseases, non-autoimmune inflammatory diseases and rejection of transplanted organs. Global ІS market is characterized by high growth rates.
 The aim of the work: analyze the immunosuppressants product nomenclature on the pharmaceutical market of Ukraine, as well as their characteristics from the point of view of state guarantees of medical care of the population.
 The research materials: the sources of special and scientific and methodical literature; The State Register of Drugs of Ukraine (as of February 1, 2023), the Register of Drugs that are subjects to reimbursement by the state guarantees program of medical care of the population, as of February 14, 2023. The methods of information search, analysis, generalization, and marketing research have been used.
 It has been established that 27 INN of immunosuppressants in the form of 134 trade names had been registered in Ukraine. Almost half of the studied drugs consisted of lenalidomide (23.13%), tacrolimus (15.67%) and mycophenolic acid (9.70%). Immunosuppressants are presented in the shape of 7 dosage forms, mostly in capsules (55.22%).
 It has been found that immunosuppressants are characterized by absolute import dependence, 127 foreign manufacturers from 27 countries have registered 133 trade names (99.25%), and the Ukrainian manufacturer (JSC "Farmak") - only one position (0.75%) and even that is from products in bulk. Germany is characterized as the country that has the highest production activity of immunosuppressants (22.83% of the enterprises had an indicator of production activity of 20.81%), and among the producers there are two pharmaceutical enterprises: Novartis Pharma Stein AG, Switzerland and Sinton Hispania S.L, Spain (production activity indicator 3.76% both).
 The Register of drugs subjects to reimbursement under the state guarantees program of medical care of the population has included 5 INN of immunosuppressants in the form of 21 trade names for people in the post-transplantation period. Four-fifths (80.95%) of them belong to expensive drugs, as evidenced by their retail price per package of UAH 1,000 or more. However, patients can receive 15 trade names free of charge, for the other 6 trade names patient’s payment ranges from 8.09 to 33.95% of retail value.
 The obtained results can serve as a prototype for the formation of the product nomenclature of drug manufacturers, wholesale pharmaceutical enterprises and pharmacies.